Roy Jacobs & Associates announces that it is investigating SciClone Pharmaceuticals, Inc. (“SciClone” or the “Company”) (NASDAQ: SCLN), a specialty pharmaceutical company, for potentially violating the federal securities laws by issuing false and misleading statements to its shareholders. For further information, please contact Roy L. Jacobs, Esq. toll-free at 1-888-884-4490 or by e-mail at email@example.com. SciClone revealed that the Securities and Exchange Commission (“SEC”) has informed the Company that the SEC has initiated a formal, non-public investigation of SciClone. The Company has also been contacted by the Department of Justice (“DOJ”), which requested that the Company meet with the DOJ regarding its compliance with the Foreign Corrupt Practices Act (“FCPA”). On this news, shares of SciClone plunged 29% to $2.48. The FCPA prohibits a company from making illicit payments to foreign officials to obtain a business advantage. If you have information that would assist Roy Jacobs & Associates in its investigation or you are interested in discussing your rights free of charge, please contact Roy L. Jacobs. Mr. Jacobs will be glad to personally speak with you.
More from Press Releases
NFL Pushes for Regulation Following Supreme Court's Sports Gambling Ruling
The Supreme Court rules that previous congressional action forbidding states from legalizing sports betting was unconstitutional.
Walmart CEO: 'We Are Transforming Globally' With Flipkart
On its investor call on Wednesday morning, Walmart discusses the Flipkart deal.
March 24 Full-Day Course Offering: Professional Approach to Trading SPX
OptionsProfits, the CBOE, and Option Pit are hosting a class on March 24 that covers a wide variety of methods to trade the S&P 500.